NCT03665207进行中（未招募）3 期
Impact of Tight Blood Glucose Control Within Normal Fasting Ranges With Insulin Titration Prescribed by the Leuven Algorithm in Adult Critically Ill Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- KU Leuven
- 入组人数
- 9,230
- 试验地点
- 4
- 主要终点
- Duration of ICU dependency
研究概览
简要总结
Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (18 years or older) admitted to a participating intensive care unit (ICU)
排除标准
- •Patients with a do not resuscitate (DNR) order at the time of ICU admission
- •Patients expected to die within 12 hours after ICU admission (= moribund patients)
- •Patients able to receive oral feeding (not critically ill)
- •Patients without arterial and without central venous line and without imminent need to place it as part of ICU management (not critically ill)
- •Patients previously included in the trial (when readmission is within 48 hours post ICU discharge, the trial intervention will be resumed)
- •Patients included in an IMP-RCT of which the PI indicates that co-inclusion is prohibited
- •Patients transferred from a non-participating ICU with a pre-admission ICU stay >7 days
- •Patients planned to receive parenteral nutrition during the first week in ICU
- •Patients suffering from diabetic ketoacidotic or hyperosmolar coma on ICU admission
- •Patients with inborn metabolic diseases
- •Patients with insulinoma
- •Patients known to be pregnant or lactating
- •Informed consent refusal
研究组 & 干预措施
Tight glucose control
Experimental
Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
干预措施: Insulin (Drug)
Liberal glucose control
Active Comparator
Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
干预措施: Insulin (Drug)
结局指标
主要结局
Duration of ICU dependency
时间窗: up to 1 year after randomization
crude number of days with need for vital organ support and time to live discharge from ICU
次要结局
- Incidence of acute kidney injury in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Incidence of new infections in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Type of new infections in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Blood glucose concentrations in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Duration of antibiotic treatment in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Time to (live) weaning from hemodynamic support(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Rehabilitation/functional outcome(up to 2 years post randomization)
- Survival(up to 4 years post randomization (in selected centers))
- ICU Mortality(up to 1 year after randomization (with and without censoring at 90 days post randomization))
- Time to (live) discharge from hospital(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Presence of clinical, electrophysiological and morphological signs of respiratory and peripheral muscle weakness in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization (in selected centers))
- Hospital Mortality(up to 1 year after randomization (with and without censoring at 90 days post randomization))
- Duration of ICU dependency(up to 90 days post randomization)
- Length of stay in hospital(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Time course of daily C-reactive protein in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Time to final (live) weaning from mechanical respiratory support in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Number of participants with need for a tracheostomy during ICU stay(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- 90-day mortality(up to 90 days post randomization)
- Duration of acute kidney injury(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Duration of hemodynamic support in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Muscle strength(up to 4 years post randomization (in selected centers))
- Rate of recovery from acute kidney injury(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Incidence of delirium in ICU (in selected centers)(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Number of participants with need for new renal replacement therapy in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Rate of recovery from new renal replacement therapy(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Number of participants with need for hemodynamic support in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Time course of markers of liver dysfunction in ICU(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Number of readmissions to the ICU within 48 hours after discharge(up to 1 year post randomization, with and without censoring at 90 days post randomization)
- Rehabilitation/Functional outcome(up to 4 years post randomization (in selected centers))
- Rate of recovery of organ function(up to 4 years post randomization (in selected centers))
- Rehabilitation/functional outcome in patients with brain injury(up to 1 year post randomization)
- Blood lipid concentrations in ICU(up to 4 years post randomization (in selected centers))
- Use of intensive care resources during index hospitalization(up to 1 year post randomization)
研究者
Greet Van den Berghe
Full professor, Head of the clinical department and laboratory of intensive care medicine
KU Leuven
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill PatientsGlucose Metabolism DisordersDiabetic Blood Glucose MonitoringCritical IllnessNCT02296372Charite University, Berlin, Germany20
Unknown
不适用
Tight Glycemic Control by Artificial PancreasPancreatic DiseaseCardiovascular DiseasesNCT00735228Kochi University400
终止
4 期
Tight Intra-Operative Glucose Control During Coronary Artery Bypass SurgeryCoronary Artery BypassNCT00394303Rabin Medical Center1,400
已完成
不适用
Blood Glucose Control in Intensive Care Patients Using the Space GlucoseControl SystemIntensive Care PatientsNCT01523665B. Braun Melsungen AG508
已完成
3 期
Tight Glycemic Control in Critical Care PatientsCritical IllnessInsulin ResistanceHyperglycemiaNCT00096421Hospital Pablo Tobón Uribe504